RU2770001C2 - Терапевтические соединения и способы - Google Patents
Терапевтические соединения и способы Download PDFInfo
- Publication number
- RU2770001C2 RU2770001C2 RU2018116565A RU2018116565A RU2770001C2 RU 2770001 C2 RU2770001 C2 RU 2770001C2 RU 2018116565 A RU2018116565 A RU 2018116565A RU 2018116565 A RU2018116565 A RU 2018116565A RU 2770001 C2 RU2770001 C2 RU 2770001C2
- Authority
- RU
- Russia
- Prior art keywords
- ser
- gly
- thr
- leu
- ala
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237835P | 2015-10-06 | 2015-10-06 | |
| US62/237,835 | 2015-10-06 | ||
| PCT/US2016/055722 WO2017062604A1 (en) | 2015-10-06 | 2016-10-06 | Therapeutic compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018116565A RU2018116565A (ru) | 2019-11-07 |
| RU2018116565A3 RU2018116565A3 (cg-RX-API-DMAC7.html) | 2020-11-03 |
| RU2770001C2 true RU2770001C2 (ru) | 2022-04-14 |
Family
ID=58488527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018116565A RU2770001C2 (ru) | 2015-10-06 | 2016-10-06 | Терапевтические соединения и способы |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11098100B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4056190A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7461620B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102716215B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108697736A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016336451B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018006811A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258931B (cg-RX-API-DMAC7.html) |
| MX (1) | MX389194B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2770001C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201802794PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017062604A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220890T1 (hr) | 2015-02-06 | 2022-10-14 | National University Of Singapore | Postupci za povećanje učinkovitosti terapijskih imunosnih stanica |
| JP7461620B2 (ja) | 2015-10-06 | 2024-04-04 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 治療用化合物及び方法 |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| EP3511340B1 (en) | 2016-08-10 | 2024-10-02 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| CU24545B1 (es) * | 2017-12-29 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Péptido antagonista de la actividad de la interleucina-15 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210017277A1 (en) * | 2018-03-14 | 2021-01-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Anti-cd33 chimeric antigen receptors and their uses |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN112912400B (zh) * | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| KR20210080460A (ko) | 2018-10-23 | 2021-06-30 | 드래곤플라이 쎄라퓨틱스, 인크. | 이종이량체성 Fc-융합된 단백질 |
| WO2020172598A1 (en) * | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| US12565658B2 (en) | 2019-05-31 | 2026-03-03 | City Of Hope | CD33 targeted chimeric antigen receptor modified T cells for treatment of CD33 positive malignancies |
| IL288713B2 (en) * | 2019-06-12 | 2026-01-01 | Univ Leland Stanford Junior | Methods for treating viral infections |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| BR112022004712A2 (pt) * | 2019-09-16 | 2022-06-14 | Gt Biopharma Inc | Compostos e métodos de imunoterapia |
| BR112022005666A2 (pt) * | 2019-09-26 | 2022-06-21 | Univ Minnesota | Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4084821A4 (en) * | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2021260960A1 (en) | 2020-04-22 | 2022-11-24 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins |
| CA3183711A1 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
| WO2022150379A1 (en) * | 2021-01-08 | 2022-07-14 | Regents Of The University Of Minnesota | Nk cell engager molecules and methods of use |
| US20250206823A1 (en) | 2021-07-30 | 2025-06-26 | Qure Biotechnology (Shanghai) Co., Ltd. | Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof |
| WO2023036270A1 (zh) | 2021-09-09 | 2023-03-16 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN118201961A (zh) * | 2021-09-16 | 2024-06-14 | Gt生物制药公司 | Pd-l1靶向融合蛋白及其使用方法 |
| US20250319128A1 (en) * | 2022-05-16 | 2025-10-16 | Northwestern University | Il15-modified car t cells for dual targeting |
| CA3253069A1 (en) * | 2022-05-31 | 2023-12-07 | Oncopeptides Innovation 1 Ab | NEW POLYPEPTIDES |
| EP4587122A1 (en) | 2022-09-15 | 2025-07-23 | Avidicure IP B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
| WO2024064446A2 (en) * | 2022-09-19 | 2024-03-28 | Duke University | Compositions and methods for the enhancement of immune cell activities against cancer |
| CN118909134A (zh) * | 2023-05-06 | 2024-11-08 | 北京新合睿恩生物医疗科技有限公司 | IL-15融合蛋白及其mRNA序列和应用 |
| CN121773132A (zh) * | 2023-05-12 | 2026-03-31 | 克里斯蒂安-阿尔伯特基尔大学 | 用于扩增nk细胞的手段和方法 |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191139A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138306A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
| RU2014100350A (ru) * | 2011-06-24 | 2015-07-27 | Ситюн | ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-Rα ДОМЕНА SUSHI |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| CN100473664C (zh) * | 2002-12-20 | 2009-04-01 | 拜奥根Idec马萨诸塞公司 | 多价淋巴毒素β受体激动剂及其治疗用途 |
| RS20050481A (sr) | 2002-12-20 | 2007-08-03 | Biogen Idec Ma Inc., | Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima |
| HUE033129T2 (en) | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
| US7235641B2 (en) * | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CN1838965B (zh) * | 2004-03-19 | 2011-07-06 | 森永乳业株式会社 | 用于癌症治疗的药品 |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP2046375B1 (en) | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
| CN101657719A (zh) | 2007-01-26 | 2010-02-24 | 路易斯维尔大学研究基金会公司 | 检测用于诊断和表征障碍的自身抗体的方法 |
| US9155798B2 (en) | 2007-08-24 | 2015-10-13 | Regents Of The University Of Minnesota | Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| EP2245153A4 (en) | 2008-02-13 | 2011-06-22 | Dyax Corp | IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP5316719B2 (ja) | 2010-08-03 | 2013-10-16 | 富士通株式会社 | 検証プログラムおよび検証装置 |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体il−15可溶性融合分子並びにその製造及び使用方法 |
| CN102251013A (zh) * | 2011-02-22 | 2011-11-23 | 北京市肿瘤防治研究所 | 一个识别肿瘤起始细胞的抗体和抗原及其应用 |
| EP2714735B1 (en) * | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| WO2013039883A1 (en) * | 2011-09-12 | 2013-03-21 | Abbvie Biotherapeutics Inc. | Artificial nk cells and uses thereof |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US9537609B2 (en) * | 2012-08-02 | 2017-01-03 | International Business Machines Corporation | Storing a stream of data in a dispersed storage network |
| BR112015006824A2 (pt) | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| US9879081B2 (en) * | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| CA2953816C (en) | 2014-06-30 | 2022-03-15 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| JP7461620B2 (ja) | 2015-10-06 | 2024-04-04 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 治療用化合物及び方法 |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3457139B1 (en) | 2017-09-19 | 2026-08-05 | Promise Proteomics | Antibody-like peptides for quantifying therapeutic antibodies |
| US11951129B2 (en) | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
-
2016
- 2016-10-06 JP JP2018517586A patent/JP7461620B2/ja active Active
- 2016-10-06 US US15/766,067 patent/US11098100B2/en active Active
- 2016-10-06 EP EP22154076.8A patent/EP4056190A1/en active Pending
- 2016-10-06 IL IL258931A patent/IL258931B/en unknown
- 2016-10-06 WO PCT/US2016/055722 patent/WO2017062604A1/en not_active Ceased
- 2016-10-06 RU RU2018116565A patent/RU2770001C2/ru active
- 2016-10-06 AU AU2016336451A patent/AU2016336451B2/en active Active
- 2016-10-06 CN CN201680071410.2A patent/CN108697736A/zh active Pending
- 2016-10-06 SG SG11201802794PA patent/SG11201802794PA/en unknown
- 2016-10-06 MX MX2018004114A patent/MX389194B/es unknown
- 2016-10-06 BR BR112018006811-0A patent/BR112018006811A2/en not_active Application Discontinuation
- 2016-10-06 SG SG10201912792YA patent/SG10201912792YA/en unknown
- 2016-10-06 KR KR1020187012492A patent/KR102716215B1/ko active Active
- 2016-10-06 EP EP16854310.6A patent/EP3359168A4/en not_active Withdrawn
-
2019
- 2019-09-05 US US16/561,627 patent/US20200087369A1/en not_active Abandoned
- 2019-09-05 US US16/561,587 patent/US11098101B2/en active Active
-
2021
- 2021-08-06 US US17/396,127 patent/US12606604B2/en active Active
- 2021-12-03 JP JP2021196759A patent/JP7274781B2/ja active Active
-
2023
- 2023-04-25 JP JP2023071386A patent/JP7555625B2/ja active Active
- 2023-09-25 AU AU2023233318A patent/AU2023233318B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014100350A (ru) * | 2011-06-24 | 2015-07-27 | Ситюн | ИММУНОЦИТОКИНЫ НА ОСНОВЕ IL-15 И IL-Rα ДОМЕНА SUSHI |
| WO2014138306A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
Non-Patent Citations (3)
| Title |
|---|
| GLEASON M.K. et al., Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Molecular cancer therapeutics, 2012, v. 11,12, p. 2674-2684.doi:10.1158/1535-7163.MCT-12-0692. * |
| MILLER J.S. Therapeutic applications: natural killer cells in the clinic. Hematology, 2013(1), p. 247-253. doi:10.1182/asheducation-2013.1.247. GLEASON M.K. et al., Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Molecular cancer therapeutics, 2012, v. 11,12, p. 2674-2684. doi:10.1158/1535-7163.MCT-12-0692. * |
| MILLER J.S. Therapeutic applications: natural killer cells in the clinic. Hematology, 2013(1), p. 247-253.doi:10.1182/asheducation-2013.1.247. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7555625B2 (ja) | 治療用化合物及び方法 | |
| US20250304701A1 (en) | Nk engager molecules and methods of use thereof | |
| EP3911371A1 (en) | Methods and compositions to improve the safety and efficacy of cellular therapies | |
| US20220315653A1 (en) | BISPECIFIC BINDING AGENT THAT BINDS TO CD117/c-KIT AND CD3 | |
| US20230210967A1 (en) | Improved peptide vaccine | |
| CA3001185C (en) | Nk engaging compounds and methods | |
| HK40082277A (en) | Therapeutic compounds and methods | |
| RU2812481C2 (ru) | Вовлекающие nk молекулы и способы их применения | |
| HK1262734A1 (en) | Therapeutic compounds and methods |